Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BPDCN

Bristol-Myers Squibb (BMS) building

BMS strikes $350m deal to boost its immuno-oncology pipeline

Will collaborate with US biotech Five Prime Therapeutics

- PMLiVE

FDA approves new indication for Pfizer/BMS’ Eliquis

Oral anticoagulant gains US approval for deep vein thrombosis use

- PMLiVE

Pfizer 2014 guidance threatened by Celebrex competition

Court overturns key patent for osteoarthritis drug

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

- PMLiVE

Pfizer recalls depression drug in US

Wrong medicine found in bottle of Effexor XR

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

- PMLiVE

Translational pharmacology: the key to ensuring safe and effective dosing

Designing pharmacokinetic and toxicokinetic studies during preclinical and early phase 1 trials will maximise a candidate’s chance of safety and efficacy success

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

- PMLiVE

GSK files Promacta for anaemia indication in US

FDA will review drug under ‘breakthrough’ designation

- PMLiVE

Gliptins don’t cause pancreatic cancer say FDA and EMA

Regulators back safety of diabetes medicine class

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links